help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hentunen, T. A.
Right arrow Articles by Roodman, G. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hentunen, T. A.
Right arrow Articles by Roodman, G. D.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*1,25-DIHYDROXYCHOLECALCIFEROL
*DEXAMETHASONE
Medline Plus Health Information
*Stem Cells
Endocrinology Vol. 140, No. 7 2954-2961
Copyright © 1999 by The Endocrine Society


ARTICLES

Characterization of Immortalized Osteoclast Precursors Developed from Mice Transgenic for Both bcl-XL and Simian Virus 40 Large T Antigen1

Teuvo A. Hentunen, Sharon H. Jackson, Hoyeon Chung, Sakamuri V. Reddy, Joseph Lorenzo, Sun Jin Choi and G. David Roodman

Department of Medicine, Division of Hematology (T.A.H., H.C., S.V.R., S.J.C., G.D.R.), University of Texas Health Science Center, San Antonio, Texas 78284; the National Institutes of Health (S.H.J.), Bethesda, Maryland 20892; the Department of Research, Veterans Administration Medical Center (J.L.), Newington, Connecticut 06111; and the Audie Murphy Veterans Administration Hospital (G.D.R.), San Antonio, Texas 78284

Address all correspondence and requests for reprints to: G. David Roodman, M.D., Ph.D., Research Service (151), Audie Murphy Veterans Administration Hospital, 7400 Merton Minter Boulevard, San Antonio, Texas 78284. E-mail: roodman{at}uthscsa.edu

We recently developed an immortalized osteoclast (OCL) precursor cell line that forms large numbers of OCLs. This cell line was derived from mice doubly transgenic for bcl-XL and large T antigen that was targeted to cells in the OCL lineage (bcl-XL/Tag cells). We have now characterized these cells in terms of their surface and enzymatic phenotype, responsiveness to osteotropic factors, and differentiation potential. The bcl-XL/Tag cells expressed interleukin-1 receptors 1 and 2, gelatinase B (MMP9), as well as Mac-1, CD16/CD32 (Fc{gamma} receptors), CD45.2 (common leukocyte marker), CD86 (costimulatory molecule expressed on B cells, follicular dendritic cells, and thymic epithelium), major histocompatibility complex I, and nonspecific esterase when cocultured with MC3T3E1 cells. However, they did not express the antigens for F4/80 (mature macrophage/dendritic cell marker) by immunostaining. Treatment of bcl-XL/Tag cells, cocultured with MC3T3E1 cells, with the combination of 1,25-dihydroxyvitamin D3 and dexamethasone induced high levels of OCL formation. The bcl-XL/Tag cells formed large numbers of OCLs when cultured with RANK ligand and macrophage colony-stimulating factor in the absence of feeder cells. In the absence of RANK ligand and a feeder cell layer, 100% of the cells differentiated into F4/80-positive cells. However, neither PTH nor PTH-related protein enhanced OCL formation by bcl-XL/Tag cells even when they were cocultured with primary osteoblasts, suggesting that they differ from primary mouse bone marrow cells in their responsiveness to PTH/PTH-related protein. Thus, bcl-XL/Tag cells have many of the properties of primary mouse OCL precursors and should be very useful for studies of OCL differentiation and divergence of OCL precursors from the macrophage lineage.




This article has been cited by other articles:


Home page
Hum Mol GenetHome page
Y. Hiruma, N. Kurihara, M. A. Subler, H. Zhou, C. S. Boykin, H. Zhang, S. Ishizuka, D. W. Dempster, G. D. Roodman, and J. J. Windle
A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment
Hum. Mol. Genet., December 1, 2008; 17(23): 3708 - 3719.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. A. Ehrlich, H. Y. Chung, I. Ghobrial, S. J. Choi, F. Morandi, S. Colla, V. Rizzoli, G. D. Roodman, and N. Giuliani
IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma
Blood, August 15, 2005; 106(4): 1407 - 1414.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y. Matsumoto, K. Tanaka, G. Hirata, M. Hanada, S. Matsuda, T. Shuto, and Y. Iwamoto
Possible Involvement of the Vascular Endothelial Growth Factor-Flt-1-Focal Adhesion Kinase Pathway in Chemotaxis and the Cell Proliferation of Osteoclast Precursor Cells in Arthritic Joints
J. Immunol., June 1, 2002; 168(11): 5824 - 5831.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Zhou, N. B. Levy, H. Xie, L. Qian, C.-Y. G. Lee, R. D. Gascoyne, and R. W. Craig
MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes
Blood, June 15, 2001; 97(12): 3902 - 3909.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1999 by The Endocrine Society